Evidence map›Paper›PMID 41514054›Full record

Trial reportNature cancer2026

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

Guangwen Yuan, Ge Lou, Jundong Li, Mei Xu, Xiaowei Liu, Danbo Wang, Keqiang Zhang, Tao Zhu, Xiumin Li, Yi Huang and 10 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04908787 (A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04908787 phase3completednot on this map

A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer.

TypeinterventionalSponsorJiangsu Simcere Pharmaceutical Co., Ltd.Ran2021 to 2024Enrolled421ConditionsOvarian CancerArmsBD0801, Paclitaxel, Placebo, Topotecan, doxorubicin liposome
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Guangwen Yuan *Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ge Lou *Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.
Jundong Li *Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Mei XuDepartment of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, China.ORCID http://orcid.org/0009-0005-2372-7530
Xiaowei LiuDepartment of Oncology, Affiliated Hospital of Jining Medical University, Jining, China.
Danbo WangDepartment of Gynecology, Liaoning Cancer Hospital and Institute, Shenyang, China.
Keqiang ZhangDepartment of Gynecologic Oncology, Hunan Cancer Hospital, Changsha, China.
Tao ZhuDepartment of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.ORCID http://orcid.org/0000-0003-0718-4941
Xiumin LiDepartment of Gynecologic Oncology, Linyi Cancer Hospital, Linyi, China.
Yi HuangDepartment of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China.
Wei DuanDepartment of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Ke WangDepartment of Gynecologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Qi ZhouDepartment of Gynecologic Oncology, Chongqing Cancer Hospital, Chongqing, China.ORCID http://orcid.org/0000-0001-5673-4263
Guiling LiDepartment of Gynecologic Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen YangClinical Sciences, Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China.ORCID http://orcid.org/0009-0006-1943-3377
Jiajing ZhangClinical Sciences, Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China.
Haolin SunState Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
Renhong TangState Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
Qingshui LiDepartment of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. 13854158117@163.com.ORCID http://orcid.org/0009-0006-9812-2322
Lingying WuDepartment of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. wulingying@csco.org.cn.ORCID http://orcid.org/0000-0003-3153-7786

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the SCORES study ( NCT04908787 ), women with ovarian cancer that progressed within 6 months after completing platinum-based therapy were randomized (2:1) to receive suvemcitug (1.5 mg kg

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmNeoplasm Recurrence, LocalOvarian NeoplasmsAdultAgedAntibodies, Monoclonal, HumanizedDouble-Blind MethodDoxorubicinFemaleHumansMiddle AgedPaclitaxelPolyethylene GlycolsProgression-Free SurvivalQuality of LifeAntibodies, Monoclonal, HumanizeddostarlimabDoxorubicinliposomal doxorubicinPaclitaxelPolyethylene GlycolsTopotecan

Identifiers

PMID41514054
PMCPMC12858396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.